SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Required)
ID: 359668Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359668
Timeline
    Description

    The National Institutes of Health (NIH) is preparing to announce the SBIR/STTR Commercialization Readiness Pilot (CRP) Program, aimed at supporting small business concerns (SBCs) in transitioning their previously funded SBIR and STTR Phase II and Phase IIB projects to commercialization. This program will provide additional support for technical assistance and later-stage research and development (R&D), which may include critical studies, IND-enabling studies, clinical trials, and regulatory assistance, thereby enhancing the potential for successful market entry of innovative health solutions. The solicitation for applications is expected to be published on October 1, 2025, with a closing date of January 5, 2026, and an estimated award date of June 1, 2026. Interested applicants can reach out to the NIH SEED Office at SEEDinfo@nih.gov or by phone at 301-827-8595 for further information.

    Point(s) of Contact
    NIH SEED (Small business Education and Entrepreneurial Development) Office of Extramural Research (OER)
    (301) 827-8595
    SEEDinfo@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce the SBIR/STTR Commercialization Readiness Pilot (CRP) Program, aimed at providing technical assistance and support for late-stage development of small business concerns (SBCs) that have previously received NIH SBIR or STTR Phase II or Phase IIB funding. This program is designed to facilitate the transition of these projects to commercialization by offering resources for activities such as independent study replication, IND-enabling studies, and regulatory assistance, which are typically not covered by standard Phase II or Phase IIB grants. Eligible applicants must be U.S.-based small businesses that meet specific ownership and operational criteria, with applications expected to be solicited following the reauthorization of the SBIR program. Interested parties can reach out to the NIH SEED Office at SEEDinfo@nih.gov or call 301-827-8595 for further information, with the estimated synopsis posting date set for October 1, 2025, and the application deadline anticipated for January 5, 2026.
    PHS 2025-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting eligible United States small business concerns (SBCs) to prepare applications for the PHS 2025-2 Omnibus Solicitation for Small Business Technology Transfer (STTR) Grant Applications, which includes Phase I, Phase II, Fast-Track, and Phase IIB grants. This opportunity aims to support innovative research and development projects that align with the NIH's mission, encouraging collaborations that leverage the technological expertise of small businesses in the health sector. The solicitation is contingent upon the reauthorization of the STTR program, with an estimated synopsis posting date of October 1, 2025, and a closing date of January 5, 2026. Interested applicants can reach out to the NIH SEED Office of Extramural Research at SEEDinfo@nih.gov or call 301-827-8595 for further information.
    NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Not Allowed) aimed at encouraging United States small business concerns (SBCs) to engage in research and development projects aligned with NIH's mission. Eligible applicants, defined as SBCs by the Small Business Administration, are invited to prepare for future submissions of Phase I, Phase II, Fast-Track, and Phase IIB grant applications, although applications are not currently being solicited. This funding opportunity is significant for fostering innovative health-related research and collaboration among small businesses and NIH institutes. Interested parties can reach out to the NIH SEED Office of Extramural Research at SEEDinfo@nih.gov or by phone at 301-827-8595 for further information, with the estimated synopsis posting date set for October 1, 2025, and a projected award date of June 1, 2026.
    Forecast to Publish a Notice of Funding Opportunity for SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for Small Business Innovation Research (SBIR) Phase IIB Bridge Awards aimed at accelerating the development of cancer-relevant technologies toward commercialization. This funding opportunity is designed for small business concerns (SBCs) that have previously received SBIR or STTR Phase II awards from any Federal agency and are seeking additional funding to transition their projects to the commercialization stage. The initiative emphasizes the importance of fostering partnerships between awardees and third-party investors to support the capital-intensive steps necessary for bringing new products and services to market. While applications are not currently being solicited, the NOFO is expected to be published in Summer 2025, with an anticipated application due date in Fall 2025. For further inquiries, interested parties can contact Jonathan Franca-Koh, Ph.D., M.B.A. at 240-618-0984 or via email at francakohjc@mail.nih.gov.
    NIH and CDC Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), in collaboration with the Centers for Disease Control and Prevention (CDC), is offering a Small Business Innovation Research (SBIR) Grant opportunity for United States small business concerns (SBCs) to submit applications for various phases of research and development, including Phase I, Phase II, Direct to Phase II, Fast-Track, and Phase IIB grants. Eligible applicants must possess the necessary research capabilities and technological expertise to support the R&D missions of the NIH and CDC, with a focus on health-related innovations. This funding opportunity is significant as it encourages collaboration among small businesses to advance health research, with applications expected to be solicited following the reauthorization of the SBIR program. Interested parties can reach out to the NIH SEED Office at SEEDinfo@nih.gov or call 301-827-8595 for further information, with the estimated synopsis posting date set for October 1, 2025, and a closing date for applications anticipated on January 5, 2026.
    Notice of Intent to Publish a Funding Opportunity Announcement for NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the Small Business Innovation Research (SBIR) Phase IIB Bridge Awards aimed at accelerating the commercialization of technologies related to heart, lung, blood, and sleep disorders. This initiative seeks to support small businesses in advancing promising biomedical projects that have previously received SBIR or STTR Phase II funding, addressing the critical funding gap that often hinders the transition to commercialization and regulatory approval. The program is designed to foster partnerships between SBIR Phase II awardees and third-party investors, with a total estimated funding of $52.5 million and individual awards capped at $3.5 million. Interested applicants should prepare to submit proposals by February 25, 2025, with the anticipated award date set for December 1, 2025.
    NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), in collaboration with the Centers for Disease Control (CDC) and the Food and Drug Administration (FDA), is inviting eligible United States small business concerns (SBCs) to prepare for the upcoming Small Business Innovation Research (SBIR) Grant opportunity, specifically under the Parent SBIR [R43/R44] Clinical Trial Not Allowed category. This funding opportunity aims to support innovative research and development projects that align with the missions of the NIH, CDC, and FDA, encouraging collaborations among small businesses with relevant technological expertise. While applications are not currently being solicited, potential applicants should note that the estimated synopsis post date is October 1, 2025, with a closing date of January 5, 2026, and an estimated award date of June 1, 2026. For further inquiries, interested parties can contact the NIH SEED Office at SEEDinfo@nih.gov or by phone at 301-827-8595.
    Forecast to Publish a Notice of Funding Opportunity for Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Small Business Transition Grant aimed at early-career scientists, specifically under the R41/R42 activity code, with a focus on supporting their transition to entrepreneurship. This initiative seeks to address the challenges of identifying the right expertise and securing funding for early-stage technology development, thereby facilitating the transfer of innovative technologies from academic laboratories to small businesses. The program is crucial for fostering technological innovation in the U.S. and is expected to award approximately 20 grants, with applications anticipated to open in Fall 2025. For further inquiries, interested parties can contact Dr. Saroj Regmi at saroj.regmi@nih.gov or call 240-276-7289.
    Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the "Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed)" to support early-career scientists in their transition to entrepreneurship. This grant aims to facilitate the development of small business concerns (SBCs) by employing researchers as Program Directors/Principal Investigators (PDs/PIs), providing them with essential entrepreneurial training, mentorship, and a structured framework for developing commercially viable biomedical technologies. The program is particularly focused on enhancing the entrepreneurial skills of scientists with strong technical expertise but limited experience in entrepreneurship, thereby aligning with NIH's mission to improve health. Interested applicants must be U.S.-based small businesses, and the application process will commence in September 2024, with a closing date of April 5, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-133.html.
    Notice of Intent to Publish a Funding Opportunity Announcement for NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the NHLBI SBIR Phase IIB Small Market Awards aimed at accelerating the commercialization of technologies for heart, lung, blood, and sleep disorders. This funding opportunity is designed to support small businesses in advancing promising biomedical projects that have previously received SBIR or STTR Phase II funding, specifically targeting products that address rare diseases or pediatric populations. With an estimated total program funding of $21 million and an award ceiling of $3.5 million, the anticipated application due date is February 25, 2025, with awards expected to be made by December 1, 2025. Interested applicants are encouraged to prepare their proposals in advance to meet the requirements integral to this initiative.